1. Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors
   F. Koinis et al, 2018, Clin Transl Oncol CrossRef
2. EML4-ALK-positive lung adenocarcinoma presenting an unusual metastatic pattern in a 29-year-old woman who is alive and well in her third year follow up:A case report
   Fatma Tokat et al, 2017, Respiratory Medicine Case Reports CrossRef
3. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.
   Richard Bayliss et al, 2016, Cell Mol Life Sci CrossRef
4. When not even four ALK inhibitors are enough
   Martin Svatoň et al, 2020, Onkologie CrossRef